Tarsus Pharmaceuticals (NASDAQ:TARS) Posts Earnings Results, Beats Estimates By $0.08 EPS

Tarsus Pharmaceuticals (NASDAQ:TARS) issued its quarterly earnings data on Tuesday. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08, Zacks reports. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%.

Tarsus Pharmaceuticals Stock Down 4.8 %

NASDAQ:TARS opened at $45.54 on Tuesday. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals has a twelve month low of $20.08 and a twelve month high of $57.28. The company has a market cap of $1.74 billion, a PE ratio of -11.95 and a beta of 1.01. The company’s 50 day moving average is $51.75 and its two-hundred day moving average is $42.90.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Oppenheimer boosted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Barclays boosted their price objective on shares of Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. The Goldman Sachs Group raised their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Tarsus Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $56.00.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.